한양대학교 ERICA 산학협력단

> 연구정보 > 연구성과 > 금주의 우수논문

한양대학교 재직중인 전임교원이 출판한 SCIE급 논문중 상위 10%이내 논문 (인문계열 SSCI 상위50%이내)
매주 업데이트

SCI-E Review

Therapeutic application of GPR119 ligands in metabolic disorders

	성명	김영미 ()
	소속	약학대학 약학과
	캠퍼스
	우수선정주	2018년 02월 1째주

Author

Choi, Yong-Won (Dept Pharm); 김영미 (Dept Pharm) corresponding author; Choi, Yong-Won (Inst Pharmaceut Sci & Technol); Kim, Young-Mi (Inst Pharmaceut Sci & Technol);

Corresponding Author Info

Kim, YM (reprint author), Hanyang Univ, Coll Pharm, Hanyangdaehakro 55, Ansan 15588, South Korea.

E-mail

ymikim12@hanyang.ac.kr

Document Type

Review

Source

DIABETES OBESITY & METABOLISM Volume:20 Issue:2 Pages:257-269 Published:2018

Times Cited

External Information

http://dx.doi.org/10.1111/dom.13062

Abstract

GPR119 belongs to the G protein-coupled receptor family and exhibits dual modes of action upon ligand-dependent activation: pancreatic secretion of insulin in a glucose-dependent manner and intestinal secretion of incretins. Hence, GPR119 has emerged as a promising target for treating type 2 diabetes mellitus without causing hypoglycaemia. However, despite continuous efforts by many major pharmaceutical companies, no synthetic GPR119 ligand has been approved as a new class of anti-diabetic agents thus far, nor has any passed beyond phase II clinical studies. Herein, we summarize recent advances in research concerning the physiological/pharmacological effects of GPR119 and its synthetic ligands on the regulation of energy metabolism, and we speculate on future applications of GPR119 ligands for the treatment of metabolic diseases, focusing on non-alcoholic fatty liver disease.

Web of Science Categories

Endocrinology & Metabolism

Funding

National Research Foundation of Korea (NRF); Korean Government [2017M3A9C8028794, 2015M3A9B6053068]

Language

English

attached file